Teva Pharmaceutical Industries Ltd. - On Thursday May 12, Doug Sommerville General Manager Teva Canada, John Jacobs GM for Teva Canada Innovation, Ben Gray VP, General Counsel, Bennett Lee and Houri Ohan
![Teva Canada Announces the Launch of AJOVY™ For the Preventive Treatment of Migraine in Adults Who Have at Least Four Migraine Days Per Month | Business Wire Teva Canada Announces the Launch of AJOVY™ For the Preventive Treatment of Migraine in Adults Who Have at Least Four Migraine Days Per Month | Business Wire](https://mms.businesswire.com/media/20200429005090/en/713670/23/teva_RGB_JPEG.jpg)
Teva Canada Announces the Launch of AJOVY™ For the Preventive Treatment of Migraine in Adults Who Have at Least Four Migraine Days Per Month | Business Wire
![Teva Canada announces availability of Aermony RespiClick™, an innovative new device for the treatment of bronchial asthma Teva Canada announces availability of Aermony RespiClick™, an innovative new device for the treatment of bronchial asthma](https://mma.prnewswire.com/media/1305988/Teva_Canada_Teva_Canada_announces_availability_of_Aermony_RespiC.jpg?p=facebook)
Teva Canada announces availability of Aermony RespiClick™, an innovative new device for the treatment of bronchial asthma
Teva Pharmaceutical Industries Ltd. - Test, test, and test again. Lisa Cameron and the Quality team at Teva Canada have their eyes on every angle of product quality to ensure our medicines
![Acetaminophen recall: Incorrect dosage on label could lead to overdose, Health Canada says | CTV News Acetaminophen recall: Incorrect dosage on label could lead to overdose, Health Canada says | CTV News](https://www.ctvnews.ca/polopoly_fs/1.5615061.1633625370!/httpImage/image.jpeg_gen/derivatives/landscape_1020/image.jpeg)
Acetaminophen recall: Incorrect dosage on label could lead to overdose, Health Canada says | CTV News
![Class not certified for abstract (“what if?”) harm respecting increased risk of cancer diagnosis: Palmer v. Teva Canada Ltd., 2022 ONSC 4690 | Alexander Holburn Beaudin + Lang LLP Class not certified for abstract (“what if?”) harm respecting increased risk of cancer diagnosis: Palmer v. Teva Canada Ltd., 2022 ONSC 4690 | Alexander Holburn Beaudin + Lang LLP](https://www.ahbl.ca/wp-content/uploads/2022/08/Banner-Class-Action-Blog.jpg)